Rhythm Pharmaceuticals (RYTM) EBT (2020 - 2025)
Historic EBT for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.8 million.
- Rhythm Pharmaceuticals' EBT fell 2002.5% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.9 million, marking a year-over-year increase of 2570.43%. This contributed to the annual value of -$260.3 million for FY2024, which is 4135.59% down from last year.
- According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' EBT is -$52.8 million, which was down 2002.5% from -$46.3 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' EBT ranged from a high of $65.8 million in Q1 2021 and a low of -$141.1 million during Q1 2024
- Over the past 5 years, Rhythm Pharmaceuticals' median EBT value was -$44.1 million (recorded in 2021), while the average stood at -$44.4 million.
- In the last 5 years, Rhythm Pharmaceuticals' EBT surged by 29247.16% in 2021 and then tumbled by 17988.78% in 2022.
- Quarter analysis of 5 years shows Rhythm Pharmaceuticals' EBT stood at -$50.9 million in 2021, then grew by 16.44% to -$42.5 million in 2022, then increased by 2.49% to -$41.4 million in 2023, then dropped by 4.69% to -$43.4 million in 2024, then dropped by 21.69% to -$52.8 million in 2025.
- Its EBT was -$52.8 million in Q3 2025, compared to -$46.3 million in Q2 2025 and -$49.4 million in Q1 2025.